Evolus earnings date
Evolus (EVL) Q3 2026 Earnings Report
DE:EVL Q3 2026 EPS Results
- Actual EPS
- -EUR 0.04
- Consensus EPS
- -EUR 0.06
- Beat/Miss
- Beat by +EUR 0.02
- One Year Ago EPS
- -EUR 0.12
DE:EVL Q3 2026 Revenue Results
- Actual Revenue
- EUR 69.79M
- Expected Revenue
- EUR 69.46M
- Beat/Miss
- Beat by +EUR 331.28K
- YoY Revenue Growth
- +13.03%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/04/2026
- Time
- After Close
- Conference Call
- Wednesday, November 4, 2026
Evolus's next earnings date is estimated for March 9, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
Q3 2026 Earnings Call Summary
The call was strongly positive, supported by 13% third-quarter revenue growth, double-digit global toxin growth, more than 40% Evolysse growth, expanding customer and consumer engagement, four consecutive quarters of positive adjusted EBITDA, lower operating expense guidance, and reaffirmed 2028 financial targets. The main challenges were softer consumer confidence, a regulatory untitled letter, seasonally lower third-quarter purchasing volumes, higher planned fourth-quarter expenses, a lower cash balance, and the absence of Sculpt revenue in 2026. Highlights significantly outweighed the lowlights.
Evolus continues to expect full year revenue between $330 million and $337 million, representing 11% to 13% growth over 2025, with the annual outlook implying a sequential increase in the fourth quarter; full year adjusted gross profit margin remains 67% to 67.5%, while full year non-GAAP operating expenses are expected to be between $210 million and $213 million, from the prior range of $212 million to $216 million, representing approximately flat to 2% growth over 2025, and full year adjusted EBITDA margin remains low to mid-single-digit. Evolysse and Estyme injectable HA gels are expected to contribute 10% to 12% of full year revenue, with no revenue contribution from Evolysse Sculpt in 2026; Evolysse Sculpt approval is anticipated in the fourth quarter of 2026 and launch in 2027, Lips submission is expected before the year-end with launch in early 2028, Profhilo approval is anticipated around 2030, and 2028 targets remain annual revenue of $450 million to $500 million and adjusted EBITDA margins of 13% to 15%.
- Revenue Growth and Positive Adjusted EBITDAThird-quarter revenue was $78 million, up 13% year-over-year, including $70.1 million of global toxin revenue and $7.9 million from injectable HA gels. Through the first nine months, revenue was $235.2 million, up 14% year-over-year. Adjusted EBITDA was positive for the fourth consecutive quarter at $1.2 million, a $4.2 million improvement versus the prior-year quarter, and reached $6.4 million through the first nine months compared with a loss of $16.5 million a year ago.
- Global Toxin and HA GrowthGlobal toxin revenue grew approximately 11% in both the third quarter and year-to-date, while the newly launched HA business grew nearly 40% in the quarter and more than 50% year-to-date. Jeuveau delivered double-digit global growth in both the quarter and year-to-date, with the company stating it continued to grow above market in the U.S. and internationally.
- Evolysse Adoption and Market Share GainsMore than 4,500 customers have purchased Evolysse. The business grew over 40% after slightly more than a year on the market, compared with a filler market growing between flat and single-digit rates in the third quarter. The company said adoption within clinics is rising, sampling initiatives generated more new-account purchases, and the number of purchasing accounts was encouraging despite the seasonally slower third quarter.
- Customer and Consumer Base ExpansionEvolus added over 500 purchasing accounts during the quarter, bringing its cumulative customer base to more than 19,000, which management estimated represents approximately two-thirds of the U.S. market purchasing injectable products. Evolus Rewards membership grew 23% year-over-year to more than 1.6 million consumers, with approximately 70% of existing patients returning for repeat treatment. The company also reported reorder rates of over 70% across its total account base.
- Operating Expense Discipline and LeverageThrough the first nine months, revenue grew 14% while non-GAAP operating expenses were reduced by 2.5%; management also described non-GAAP operating expenses as nearly flat during the period. Third-quarter GAAP operating expenses were $59.1 million versus $61.7 million in the second quarter, while non-GAAP operating expenses were $50.3 million versus $53.3 million.
- Gross Margin PerformanceThird-quarter reported gross margin was 65%, and adjusted gross margin was 66.1%. Year-to-date gross margins remained flat with the prior year, and full-year gross margin guidance was unchanged.
- Portfolio Expansion and International RightsEvolus added skin quality as a third pillar of its U.S. facial injectable pipeline through its partnership with IBSA for Profhilo. Following the European launch of Estyme, the company expanded its Symatese relationship in August to include Canada, Australia and New Zealand, giving Evolus exclusive rights to the Evolysse portfolio in every market where it currently offers Jeuveau and Nuceiva.
- Pipeline Progress and Planned Product LaunchesEvolysse Sculpt remains under FDA review, with approval anticipated in the fourth quarter of 2026 and launch expected in the first quarter of 2027. Evolysse Lips is nearing final stages, with a PMA submission anticipated before year-end and launch expected in early 2028. Profhilo's FDA development program is underway, with approval anticipated around 2030. Together, these programs support plans for three product launches over the next four years.
- Hair Growth Option AgreementEvolus entered an early-stage option agreement for a procedure-based injectable hair-growth asset. The program is targeting local delivery, a well-characterized therapeutic agent, an in-office procedure and a three-month treatment interval. The option can be exercised based on actual human data before Evolus commits to acquiring the company and the full development program.
- Capital Flexibility and Disciplined Business DevelopmentThe company ended the quarter with $41.7 million in cash and cash equivalents and access to approximately $120 million of additional nondilutive capacity. The Profhilo partnership includes no upfront or milestone payments, and management said it remains active in discussions regarding biostimulator assets while maintaining discipline around agreement terms and structure.
- Updated Expense Outlook and Reaffirmed Long-Term TargetsFull-year revenue guidance was reaffirmed at $330 million to $337 million, representing 11% to 13% growth over 2025. Adjusted gross profit margin guidance remained 67% to 67.5%, and the adjusted EBITDA margin outlook remained low to mid-single-digit. Non-GAAP operating expense guidance was lowered to $210 million to $213 million from $212 million to $216 million, with the midpoint reduced by $2.5 million. Evolus also reaffirmed its 2028 objectives of $450 million to $500 million in annual revenue and adjusted EBITDA margins of 13% to 15%.
- Continued Investment in Commercial PrioritiesManagement said it continues to invest in Jeuveau, the expansion of Evolysse and Estyme, and pipeline programs supporting future growth while maintaining financial discipline. Evolysse and Estyme injectable HA gels are expected to contribute 10% to 12% of full-year revenue.
- Positive Market and Portfolio TailwindsManagement described the global aesthetics market as healthy, with consumers continuing to prioritize beauty and appearance despite softer consumer confidence. The company said the U.S. category is strengthening, supported in part by broader adoption of GLP-1 therapies bringing new patients into aesthetic practices and creating additional treatment needs following weight loss.
DE:EVL Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Mar 09, 2027 | 2026 (Q4) | 0.05- | 0.04 | ― | ― |
| Nov 04, 2026 | 2026 (Q3) | -0.06-0.04 | -0.12 | 65.91% (+0.08) | |
| Aug 05, 2026 | 2026 (Q2) | -0.030.01 | -0.22 | 102.83% (+0.23) | |
| May 04, 2026 | 2026 (Q1) | -0.10-0.04 | -0.13 | 69.13% (+0.09) | |
| Mar 03, 2026 | 2025 (Q4) | 0.030.04 | 0.03 | 33.33% (+0.01) | |
| Nov 05, 2025 | 2025 (Q3) | -0.15-0.12 | -0.15 | 18.52% (+0.03) | |
| Aug 05, 2025 | 2025 (Q2) | -0.10-0.22 | -0.03 | -533.33% (-0.19) | |
| May 07, 2025 | 2025 (Q1) | -0.12-0.13 | -0.07 | -79.52% (-0.06) | |
| Mar 04, 2025 | 2024 (Q4) | 0.020.03 | -0.11 | 126.61% (+0.14) | |
| Nov 06, 2024 | 2024 (Q3) | -0.11-0.15 | -0.15 | 1.82% (+0.00) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
